Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathilde Guerin

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Bulletin Du Cancer|March 21, 2015
[Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers]Mathilde Guerin, Renaud Sabatier, Anthony Gonçalves
Bulletin Du Cancer|July 6, 2026
[Update: Evolution in the management of metastatic urothelial carcinomas]Clémentine Gaucher, Cécile Vicier, Mathilde Guerin
World Journal of Surgical Oncology|October 1, 2013
Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-upMathilde Guerin, Naji Salem, Jochen Walz, et al.
Cancers|June 18, 2020
New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?piEssia Mezni, Cécile Vicier, Mathilde Guerin, et al.
Frontiers in Immunology|October 3, 2022
Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case reportRoxane Mari, Mathilde Guerin, Cécile Vicier, et al.
World Journal of Urology|June 27, 2020
Metastatic hormone sensitive prostate cancer: local treatment strategiesJochen Walz, Geraldine Pignot, Sami Fakhfakh, et al.
Expert Review of Proteomics|November 5, 2016
How may targeted proteomics complement genomic data in breast cancer?Mathilde Guerin, Anthony Gonçalves, Yves Toiron, et al.
Oncotarget|May 12, 2015
Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancerChristine Pasero, Gwenaëlle Gravis, Samuel Granjeaud, et al.
Frontiers in Oncology|October 26, 2019
Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell CarcinomaEmilien Billon, Jochen Walz, Serge Brunelle, et al.
Journal of Translational Medicine|December 5, 2025
The plasma nanoDSF denaturation profiles predict the presence of breast cancerMathilde Guerin, Rémi Eyraud, Philippe Tsvetkov, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Bulletin Du Cancer|March 21, 2015
[Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers]Mathilde Guerin, Renaud Sabatier, Anthony Gonçalves
Bulletin Du Cancer|July 6, 2026
[Update: Evolution in the management of metastatic urothelial carcinomas]Clémentine Gaucher, Cécile Vicier, Mathilde Guerin
World Journal of Surgical Oncology|October 1, 2013
Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-upMathilde Guerin, Naji Salem, Jochen Walz, et al.
Cancers|June 18, 2020
New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?piEssia Mezni, Cécile Vicier, Mathilde Guerin, et al.
Frontiers in Immunology|October 3, 2022
Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case reportRoxane Mari, Mathilde Guerin, Cécile Vicier, et al.
World Journal of Urology|June 27, 2020
Metastatic hormone sensitive prostate cancer: local treatment strategiesJochen Walz, Geraldine Pignot, Sami Fakhfakh, et al.
Expert Review of Proteomics|November 5, 2016
How may targeted proteomics complement genomic data in breast cancer?Mathilde Guerin, Anthony Gonçalves, Yves Toiron, et al.
Oncotarget|May 12, 2015
Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancerChristine Pasero, Gwenaëlle Gravis, Samuel Granjeaud, et al.
Frontiers in Oncology|October 26, 2019
Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell CarcinomaEmilien Billon, Jochen Walz, Serge Brunelle, et al.
Journal of Translational Medicine|December 5, 2025
The plasma nanoDSF denaturation profiles predict the presence of breast cancerMathilde Guerin, Rémi Eyraud, Philippe Tsvetkov, et al.
Pageof 2